葛兰素史克Glaxosmithkline（GSK）2024年20-F年度报告「LSE」（英文版）（323页）.pdf

1、As filed with the Securities and Exchange Commission on March 3,2025UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIES EXCHANGE ACT OF 1934OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIE

2、S EXCHANGE ACT OF 1934For the fiscal year ended December 31,2024OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934Date of event requiring this shell company report For

3、 the transition period from toCommission file number 1-15170 GSK plc(Exact name of Registrant as specified in its charter)England(Jurisdiction of incorporation or organization)79 New Oxford Street,London,WC1A 1DG,England(Address of principal executive offices)Victoria Whyte Company Secretary GSK plc

4、79 New Oxford Street,London,WC1A 1DG England+44 20 8047 (Name,Telephone,E-mail and/or Facsimile number and Address of Company Contact Person)Securities registered or to be registered pursuant to Section 12(b)of the Act:Title of Each ClassTrading Symbol(s)Name of Each Exchange On Which Registered Ame

5、rican Depositary Shares,each representing 2 Ordinary Shares,Par value 31 14 penceGSKNew York Stock Exchange3.625%Notes due 2025GSK/25New York Stock Exchange3.875%Notes due 2028GSK/28New York Stock Exchange3.375%Notes due 2029GSK/29New York Stock Exchange6.375%Notes due 2038GSK/38New York Stock Excha

6、nge4.200%Notes due 2043GSK/43New York Stock Exchange Securities registered or to be registered pursuant to Section 12(g)of the Act:None(Title of class)Securities for which there is a reporting obligation pursuant to Section 15(d)of the Act:None(Title of class)Indicate the number of outstanding share